1 posts
Communicating effectiveness of boosters

Statisticians David Spiegelhalter and Anthony Masters for The Guardian on reframing risk estimates: An earlier UKHSA study estimated two Pfizer/BioNTech doses gave around 99.7% (97.6% to near-100%) protection against Delta-infected hospitalisation, but after 20 weeks that effectiveness waned to 92.7% (90.3% to 94.6%). This estimated decline for people over 16 may not sound much, but if we look at it in terms of “lack of protection”, their estimated vulnerability relative...

0 0